Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

BACKGROUND

Fingolimod is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite an established effect on heart rate, the effect of fingolimod on cardiac repolarization is not completely known.

METHODS

Twenty-seven patients with RRMS underwent 24-hr ambulatory ECG before fingolimod (baseline), at the day of fingolimod initiation (1D) and after three-month treatment (3M). The mean values of RR-interval as well as QT-interval corrected by Bazzet's (QTcBaz) and Fridericia's (QTcFri) formula were compared between baseline, 1D, and 3M over 24-hr period as well as at daytime and nighttime.

RESULTS

QTcBaz over 24-hr was shorter at 1D (414 ± 20 ms,  < .001) and at 3M (414 ± 20 ms,  < .001) than at baseline (418 ± 20 ms). In contrast, QTcFri over 24-hr was longer at 1D (410 ± 19 ms,  < .001) but similar at 3M (406 ± 19 ms,  = .355) compared to baseline (407 ± 19 ms). Daytime QTcBaz was shorter at 1D ( < .001) and at 3M ( = .007), whereas daytime QTcFri was longer at 1D ( < .05) but similar at 3M ( = ns) compared to baseline. During the night, changes were observed neither in QTcBaz nor in QTcFri between baseline, 1D, and 3M.

CONCLUSIONS

Changes in cardiac repolarization after fingolimod initiation were mild and occurred at daytime. Ambiguously, QTcBaz demonstrated shortening, whereas QTcFri showed prolongation in cardiac repolarization after fingolimod initiation. The formula applied for QT-interval correction needs to be taken carefully into account as evaluating pharmacovigilance issues related to fingolimod.